VITALE, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 28.266
AS - Asia 15.103
EU - Europa 7.287
AF - Africa 2.426
SA - Sud America 2.388
Continente sconosciuto - Info sul continente non disponibili 460
OC - Oceania 242
Totale 56.172
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.820
SG - Singapore 4.636
CN - Cina 2.530
VN - Vietnam 2.336
IT - Italia 1.946
HK - Hong Kong 1.498
BR - Brasile 1.377
BD - Bangladesh 730
FI - Finlandia 596
DE - Germania 583
FR - Francia 560
IN - India 423
PL - Polonia 388
GB - Regno Unito 304
SE - Svezia 290
UA - Ucraina 269
RU - Federazione Russa 244
IQ - Iraq 240
CA - Canada 236
NL - Olanda 232
TR - Turchia 212
AR - Argentina 204
JP - Giappone 193
MX - Messico 161
PK - Pakistan 157
SA - Arabia Saudita 157
PH - Filippine 148
ID - Indonesia 131
ZA - Sudafrica 129
AT - Austria 124
EC - Ecuador 123
ES - Italia 117
VE - Venezuela 113
CO - Colombia 110
IE - Irlanda 104
AE - Emirati Arabi Uniti 101
CL - Cile 95
JO - Giordania 92
JM - Giamaica 90
UZ - Uzbekistan 90
AL - Albania 84
CR - Costa Rica 84
PY - Paraguay 84
MA - Marocco 83
KR - Corea 82
AO - Angola 81
CI - Costa d'Avorio 80
PE - Perù 79
AZ - Azerbaigian 78
MY - Malesia 77
BO - Bolivia 76
TH - Thailandia 76
CZ - Repubblica Ceca 74
EG - Egitto 74
KE - Kenya 74
GR - Grecia 71
SN - Senegal 71
TN - Tunisia 71
DO - Repubblica Dominicana 70
LB - Libano 70
NP - Nepal 70
RS - Serbia 70
BG - Bulgaria 69
CW - ???statistics.table.value.countryCode.CW??? 69
TJ - Tagikistan 69
ET - Etiopia 68
RO - Romania 68
HN - Honduras 67
GT - Guatemala 66
UY - Uruguay 66
BA - Bosnia-Erzegovina 65
BE - Belgio 65
PS - Palestinian Territory 65
BZ - Belize 64
CM - Camerun 64
MK - Macedonia 64
BJ - Benin 63
CH - Svizzera 63
IL - Israele 62
LA - Repubblica Popolare Democratica del Laos 62
MR - Mauritania 62
MU - Mauritius 62
NI - Nicaragua 62
TW - Taiwan 62
UG - Uganda 62
GA - Gabon 61
HU - Ungheria 61
MD - Moldavia 61
ME - Montenegro 61
PA - Panama 61
MN - Mongolia 60
DZ - Algeria 59
GH - Ghana 59
KZ - Kazakistan 59
MG - Madagascar 59
SK - Slovacchia (Repubblica Slovacca) 59
BF - Burkina Faso 58
GE - Georgia 58
ZM - Zambia 58
IR - Iran 57
Totale 52.948
Salva come PNG Salva come JPEG
Città #
Ashburn 3.122
Fairfield 3.065
San Jose 2.834
Singapore 2.828
Woodbridge 1.856
Houston 1.467
Chandler 1.365
Hong Kong 1.357
Ann Arbor 1.202
Seattle 1.185
Wilmington 981
Cambridge 978
Ho Chi Minh City 650
Santa Clara 573
Jacksonville 535
Hanoi 504
Los Angeles 468
Beijing 442
Boardman 399
San Diego 389
New York 374
Princeton 331
Helsinki 309
Lauterbourg 277
Des Moines 270
Bytom 265
Dong Ket 244
Medford 213
Roxbury 182
Padova 176
Munich 175
Buffalo 142
Nanjing 140
Milan 139
São Paulo 128
Da Nang 127
Guangzhou 127
Rome 125
Tokyo 124
Chicago 120
Council Bluffs 117
Orem 107
Baghdad 96
Haiphong 90
Dallas 86
Dublin 86
Amman 85
Warsaw 84
Tashkent 80
Abidjan 75
Shenyang 75
London 71
Baku 70
Dakar 70
Frankfurt am Main 69
San José 67
Luanda 65
Hefei 64
Dushanbe 63
Vienna 63
Atlanta 62
Istanbul 62
Nairobi 61
Kampala 60
Johannesburg 59
Libreville 59
Ulan Bator 59
Lusaka 58
Addis Ababa 57
Lahore 57
Nuremberg 57
Panama City 57
Vientiane 57
Montevideo 56
Montreal 56
Amsterdam 55
Cotonou 55
Managua 55
Naples 55
Antananarivo 54
Nouakchott 54
Podgorica 54
Shanghai 54
Willemstad 54
Accra 53
Conakry 53
Tianjin 53
Kingston 52
Jeddah 51
Toronto 51
Turku 51
Harare 50
Praia 50
Andorra la Vella 49
Bridgetown 49
Nassau 49
Castries 48
Djibouti 48
Nanchang 48
Tirana 48
Totale 33.941
Salva come PNG Salva come JPEG
Nome #
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database 376
The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study 324
Salvataggio d’organo attraverso emitrasposizione porto-cavale in trombosi porto-spleno- meseraica acuta dopo OLTx
G. 318
Use of N-acetylcysteine during liver procurement: A prospective randomized controlled study. 308
Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics 307
When to perform hepatic resection for intermediate-stage hepatocellular carcinoma 304
Monofocal hepatocellular carcinoma: How much does size matter? 300
Treatment of hepatocellular carcinoma in the Precision Medicine era: from treatment stage migration to therapeutic hierarchy 298
Adjuvant chemotherapy for transplanted hepatocellular carcinoma patients: impact on survival or HCV recurrence timing 297
BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. 294
Circulating free DNA in the progression of liver damage to hepatocellular carcinoma 290
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma 280
LAPAROSCOPIC ABLATION AND SALVAGE TRANSPLANTATION FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA 280
Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma 278
Management of hepatocellular carcinoma recurrence after liver transplantation 277
THE USE OF OCTOGENARIAN DONORS FOR LIVER TRANSPLANT 276
Model for end-stage liver disease-sodium and survival benefit in liver transplantation. 275
Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients 274
Cost-effectiveness of Pre-Transplant Sofosbuvir for Preventing Recurrent HCV Infection after Liver Transplantation. 272
Prospective validation of the Barcelona Clinic Liver Cancer staging system 272
A novel approach to severe acute pancreatitis in sequential liver-kidney transplantation:the first report on the application of VAC therapy 271
Growth hormone/insulin-like growth factor 1 axis recovery after liver transplantation: A preliminary prospective study 271
146 EARLY INTRODUCTION OF EVEROLIMUS IN DE NOVO LIVER TRANSPLANTATION: A MULTICENTER RANDOMIZED CLINICAL TRIAL (EPOCAL) 270
Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus-related liver carcinogenesis 269
Videolaparoscopic microwave ablation in patients with HCC at a European high-volume center: Results of 815 procedures 269
A Pig Model of Hemivascular Liver Occlusion for The Study of Ischemia-Reperfusion Injury: Use of an Infrared System for Detecting Ischemic Areas 267
Syngeneic living-donor liver transplantation for hemangioendothelioma: a clinical model for studying liver regeneration 266
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database 265
Alcohol abuse and de novo tumors in liver transplantation 263
Liver transplantation for the management of hepatoblastoma 262
Liquid biopsy in hepatocellular carcinoma: Where are we now? 261
CiThroModel Improves Prediction of Symptomatic Venous Thromboembolism in Hospitalized Patients With Cirrhosis Without Hepatocellular Carcinoma 261
Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma 260
Partial hepatectomy as first-line treatment for patients with hepatocellular carcinoma 259
Termoablazione con microonde nel trattamento della recidiva locale di epatocarcinoma dopo trapianto ortotopico di fegato.
 259
Drop-out rate from the liver transplant waiting list due to HCC progression in HCV-infected patients treated with direct acting antivirals. 259
Prognostic impact of model for end-stage liver disease score in patients undergoing liver transplantation with suboptimal livers. 254
Donor-Model for End-Stage Liver Disease and Donor-Recipient Matching in Liver Transplantation 254
Liver radiofrequency ablation as emergency treatment for a ruptured hepatocellular carcinoma: a case report 252
The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria–In Patients Waiting for Liver Transplantation 252
Risk Factors for Early Mortality in Liver Transplant Patients 251
Who Fares Worse After Liver Transplantation? Impact of Donor and Recipient Variables on Outcome: Data from a Prospective Study. 249
Antiviral treatment for HCV recurrence after liver transplantation: when, how much and for how long? 248
Prognostic Evaluation of the Donor Risk Index Among a Prospective Cohort of Italian Patients Undergoing Liver Transplantation 247
Laparoscopic Ablation of Hepatocellular Carcinoma in Cirrhotic Patients Unsuitable for Liver Resection or Percutaneous Treatment: A Cohort Study 247
Very Early Introduction of Everolimus in De Novo Liver Transplantation: Results of a Multicenter, Prospective, Randomized Trial 246
A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. 245
Isoniazid-related fulminant hepatic failure in a child: assessment of the native liver's early regeneration after auxiliary partial orthotopic liver transplantation. 244
A novel approach to severe acute pancreatitis in sequential liver-kidney transplantation: the first report on the application of VAC therapy 244
Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma 244
Microwave Thermal Ablation for Hepatocarcinoma: Six Liver Transplantation Cases 242
Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma 242
Hierarchically Positioning Laparoscopic Microwave Ablation in the Therapeutic Span of Early Hepatocellular Carcinoma: A Real-Life Comparative Analysis 241
HCV eradication is not associated with drop-out due to HCC progression in patients awaiting liver transplantation: A monocentric experience 241
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 240
Liver Resection Associated With Mini Porto-Caval Shunt as Salvage Treatment in Patients With Progression of Hepatocellular Carcinoma Before Liver Transplantation: A Case Report 237
Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. 237
Thoracoscopic Ablation of Critically Located Liver Tumors: A Safety and Efficacy Cohort Study 237
Liver autotransplantation for the treatment of unresectable hepatic metastasis: an uncommon indication-a case report. 237
Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation 235
A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis 235
Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. 234
Defining the possible therapeutic benefit of lymphadenectomy among patients undergoing hepatic resection for intrahepatic cholangiocarcinoma 234
A multicenter pilot prospective study comparing Celsior and University of Wisconsin preserving solutions for use in liver transplantation 232
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 232
The survival benefit of liver transplantation in hepatocellular carcinoma patients 231
Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the milan criteria 230
A novel approach to severe acute pancreatitis in sequential liver-kidney transplantation: the first report on the application of VAC therapy 229
Liver transplantation using suboptimal grafts: impact of donor harvesting technique. 228
Nash Up, Virus Down: How the Waiting List Is Changing for Liver Transplantation: A Single Center Experience from Italy 228
A PRIORITIZATION MODEL FOR LIVER TRANSPLANTATION BASED ON A DUAL WAITING LIST: A PROSPECTIVE CONTROLLED STUDY 227
Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium 226
The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? 226
Colon Rectal Liver Metastases: The Role of the Liver Transplantation in the Era of the Transplant Oncology and Precision Medicine 225
Erratum to "A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list" [J Hepatol 2013;60:290-297]. 224
SCCA-IgM in hepatocellular carcinoma patients treated with transarterial chemoembolization: gender-related differences 224
Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma? 222
Hepatic Resection for Disappearing Liver Metastasis: a Cost-Utility Analysis 221
LIVER TRANSPLANTATION FOR COMBINED HEPATOCELLULAR CARCINOMA AND CHOLANGIOCARCINOMA A CASE MATCH ANALYSIS 221
Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference 221
Prospective validation of a new priority allocation model for liver transplant candidates: an interim analysis. 221
The survival benefit of laparoscopic ablation over trans-arterial chemoembolization in patients with hepatocellular carcinoma ineligible for liver resection or percutaneous ablation 220
Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies. 219
Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor 219
Identification of an upper limit of tumor burden for downstaging in candidates with hepatocellular cancer waiting for liver transplantation: A west–east collaborative effort 219
EXTREME MARGINAL DONOR: SEVERE HYPOTHERMIA AS A RARE PRESERVATION CONDITION FOR EXPLANTABLE ORGANS - A CASE REPORT 218
Liver Retransplantation for Hepatic Abscess Due to Hepatic Artery Thrombosis: A Case Report 218
Alcohol- and substance-dependent subjects: The correlated factors in qualifying for liver transplantation 217
Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC 215
A multi-institutional analysis of elderly patients undergoing a liver resection for intrahepatic cholangiocarcinoma 214
Prognostic Factors for 10-Year Survival in Patients With Hepatocellular Cancer Receiving Liver Transplantation 213
Skin cancer and other cutaneous disorders in liver transplant recipients. 213
Restaging patients with hepatocellular carcinoma before additional treatment decisions: a multicenter cohort study 213
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 212
Laparoscopic microwave ablation in patients with hepatocellular carcinoma: A prospective cohort study 211
Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma 209
Development and Validation of a Comprehensive Model to Estimate Early Allograft Failure Among Patients Requiring Early Liver Retransplant 209
Estimation of the harm to the waiting list as a crucial factor in the selection of patients with hepatocellular carcinoma for liver transplantation. 208
De novo tumors are a major cause of late mortality after orthotopic liver transplantation. 208
Survival Benefit of Transplantation for Recurrence of Hepatocellular Carcinoma After Liver Resection 208
Totale 24.832
Salva come PNG Salva come JPEG
Categoria #
all - tutte 154.164
article - articoli 128.052
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 539
Totale 282.755
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.304 0 476 437 248 133 217 1.111 197 136 58 551 740
2022/20232.776 553 269 132 320 407 411 35 161 303 28 114 43
2023/20241.504 114 233 144 119 92 110 131 64 54 109 157 177
2024/20256.115 10 347 295 200 784 198 261 462 498 255 1.081 1.724
2025/202627.995 1.024 2.169 3.464 4.166 2.370 1.218 3.821 2.429 3.197 1.718 1.341 1.078
2026/20271.313 1.181 132 0 0 0 0 0 0 0 0 0 0
Totale 56.172